Targeting the CXCL8-CXCR1/CXCR2 axis by antagonizing CXCR2 promotes tumor progression in vivo by impeding DC activation or recruitment, leading to the opposite effect of antitumor immunity. The gene discussed is CXCL8; the disease is neoplasm.